Eikon Therapeutics logo

Eikon Therapeutics Funding & Investors

Eikon Therapeutics is a biopharmaceutical company employing revolutionary technology at the interface of biology, engineering, and chemistry to discover novel treatments for life-threatening diseases. Eikon’s discovery platform is built on groundbreaking innovations from its founders (Nobel Prize, 2014), culminating in the creation of microscopes that enable real-time, molecular-resolution measurements of protein movement in living cells.

https://eikontx.com/

Total Amount Raised: $772,000,000

Eikon Therapeutics Funding Rounds

  • Series C

    $106,000,000

  • Series B

    $518,000,000

    Series B Investors

    UC Investments
    T. Rowe Price
    EcoR1 Capital
    CPP Investments
    Schroders
    Hartford Healthcare Endowment
    Harel Insurance Investments & Financial Services
    StepStone Group
    ADIA (Abu Dhabi Investment Authority)
    Soros Capital Management
    AME Cloud Ventures
    General Catalyst
    E15 VC
    Column Group
    Innovation Endeavors
    Lux Capital
    Foresite Capital
    Horizons Ventures
  • Series A

    $148,000,000

    Series A Investors

    Column Group
    Lux Capital
    Innovation Endeavors
    Foresite Capital
    WPSS.bio
    TCG Crossover Management
Funding info provided by Diffbot.